Keywords: merck, kgaa, buys, rights, stimuvax, germany-based, licensed

Merck KGaA buys more rights to Stimuvax

Article | 12 January 2009

Print This

Germany-based Merck KGaA has licensed the rights to Stimuvax, a vaccine in Phase III development for non-small cell lung cancer, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in